tbuckley/cabot-search huggingface dataset:
Electrophysiological diagnosis of participation of accessory pathway in patients with paroxysmal supraventricular tachycardia.
Authors: Meiichi Ito, Susumu Shinoda, Michio Nagashima, Kenzo Chimori, Yasumichi Kinoshita, Hikoyuki Suzuki
Journal: Circulation (1981)

Electrophysiological studies were performed on 34 patients whose reentrant circuit of paroxysmal supraventricular tachycardia (PSVT) involved normal atrioventricular (AV) conduction system as the antegrade limb and either overt (25 patients) or concealed (9 patients) accessory AV pathway as the retrograde limb. The diagnosis of this mechanism was made by one or more of the following: 1) eccentric retrograde atrial activation sequence; 2) effect of bundle branch block on ventriculoatrial (VA) conduction time; 3) paradoxically premature atrial capture; 4) atrial capture by premature ventricular stimulation of VA conduction time with retrograde during PSVT; 5) no significant prolongation of VA conduction time with retrograde atrial activation sequence to that of PSVT during incremental and premature ventricular stimulation; 6) shortening of cycle length with constant H-V and V-A intervals after atropine administration. The participation of accessory pathway in PSVT circuit should be decided by as many of the above-mentioned findings or procedures as possible for optimal therapy. Electrophysiological studies have led to the recognition that accessory pathway, functionally silent during antegrade conduction, is responsible for some patients with PSVT. If the mechanisms of PSVT were more carefully analyzed, the recognition of PSVT cases involving accessory pathway would increase.
Detection of human parvovirus B19 DNA in 22% of 1815 cutaneous biopsies of a wide variety of dermatological conditions suggests viral persistence after primary infection and casts doubts on its pathogenic significance
Authors: C. Santonja, A. Santos-Briz, G. Palmedo, H. Kutzner, L. Requena
Journal: British Journal of Dermatology (2017)

Human parvovirus B19 (B19V) has been associated with a number of dermatological and systemic conditions, including myocarditis and autoimmune syndromes. To determine the frequency of B19V DNA detection in a large dermatopathology practice, and to characterize the histopathological patterns involved. We selected for polymerase chain reaction (PCR) detection of B19V a total of 1815 skin biopsies pertaining to entities allegedly related to B19V, as well as cases suspected clinically of representing paraviral exanthemas. Immunohistochemical detection of B19V viral protein 2 (VP2) was performed in 92 PCR‐positive cases. B19V DNA was found by PCR in 402 out of 1825 biopsy specimens (22%). VP2 protein was identified by immunohistochemistry in only three instances of papular purpuric 'gloves‐and‐socks' syndrome. As the virus has the capacity to persist in different tissues (including the skin) for long periods, it could represent merely an innocent bystander, so no pathogenetic significance can be inferred from the PCR positivity for B19V in the vast majority of dermatological conditions studied.
Transdermal granisetron is effective in prevention of acute-delayed emesis in patients with glioblastoma multiforme (gbm) treated with temozolomide (tmz): results from a monocentric experience
Authors: G. Lanzetta, M. Corona, P.T. Falbo, C. Spoto, A. Iannace, L. De Filippis, A. Rozzi
Journal: Annals of Oncology (2016)
Cerebral Vasculopathy Outcome in a Sickle Cell Anemia (SCA) Newborn Cohort Screened Early with Transcranial Doppler
Authors: Francoise Bernaudin, Suzanne Verlhac, Cécile Arnaud, Annie Kamdem, Lena Coïc, Emmanuelle Lesprit, Isabelle Hau, Philippe Reinert, Christophe Delacourt
Journal: Blood (2008)
Stratification of patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiation (ChR), according to Valentini's nomograms (VN) and the Neoadjuvant Rectal Score (NAR). External validation in a single Institution.
Authors: S. Roselló Keränen, M. Frasson, E. García-Granero, S. Navarro, S. Campos, E. Jordá, P. Esclapez, S. García-Botello, B. Flor, A. Espí, A. Cervantes
Journal: Annals of Oncology (2016)
SURG-09. AGENTS FOR FLUORESCENCE GUIDED GLIOMA SURGERY: REVIEW OF PRECLINICAL AND CLINICAL RESULTS
Authors: Joeky Senders, Ivo Muskens, Rosalie Schnoor, Aditya Karhade, Dave Cote, Timothy Smith, Marike Broekman
Journal: Neuro-Oncology (2016)

Gross total resection (GTR) of gliomas is associated with improved survival. Fluorescence guided surgery (FGS) is a technique used to enhance visualization of tumor margins in order to increase the extent of tumor resection. The aim of this paper was to systematically review all pre-clinical and clinical studies that investigated fluorescent agents for application in FGS of gliomas. We searched Pubmed and Embase databases for all potentially relevant studies up to march 2016. We compared the usefulness of the fluorescent agents by assessing the following outcomes: GTR rate, overall and progression free survival, sensitivity and specificity in discriminating tumor and healthy brain tissue, tumor-to-normal ratio (TNR) of fluorescent signal and incidence of adverse events. The search strategy resulted in 1696 articles that were screened by titles and abstracts. After full-text screening, 98 articles fulfilled the inclusion criteria. Clinically, forty-four studies, including two randomized control trails (RCTs), tested 5-ALA, eleven studies tested fluorescein, two studies tested indocyanine green, one study tested hypericin and five studies tested endogenous fluorophores in FGS of gliomas. Twenty-four other fluorescent agents were identified that have only been tested pre-clinically. Overall, 5-ALA and fluorescein offer the best improvement in GTR and survival of all clinically tested agents. Molecular targeting agents (e.g. fluorophore labeled anti-EGFR antibodies) offer promising results on histological accuracy but are still in the pre-clinical phase. For FGS in glioma surgery, 5-ALA and fluorescein offer the best improvement in GTR rate and survival. However, several pre-clinically tested agents may be interesting future alternatives.
Human Antagonistic Anti-CD40 Antibody, CHIR-12.12, Inhibits CD40-Mediated Survival of Chronic Lymphocytic Leukemia B Cells Leading to Cellular Apoptosis.
Authors: Anu Cherukuri, Edward Kadel, Sang H. Lee, Cheryl Goldbeck, Carla Heise, Mohammad Luqman, Sharon L. Aukerman, Natasha Aziz, Susan O’Brien, William G. Wierda, Bahija Jallal
Journal: Blood (2005)
Binding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase
Authors: S. Soverini, G. Tasco, T. Grafone, S. Colarossi, A. Gnani, M. Baccarani, R. Casadio, G. Martinelli
Journal: Journal of Clinical Oncology (2007)

7049 Background: Bosutinib (SKI-606) is a 4-anilino-3-quinolinecarbonitrile Src/Abl kinase inhibitor. The crystal structure of Abl kinase domain in complex with bosutinib has not yet been determined and the mode of binding of this inhibitor is therefore unknown. Methods: In the present study, we used a molecular docking approach to investigate the following: a) Which Abl conformation(s) bosutinib is more likely to bind? b) Which Abl residues are likely to be involved in bosutinib binding? c) Which imatinib-resistant Abl mutants bosutinib is likely to be active against? A three-dimensional model of bosutinib was generated by Chemsketch ( http://www.acdlabs.com ). Modelling of the human Abl kinase in its inactive (closed) conformation was performed with the software Modeller, v7.7 ( http://salilab.org/modeller ) adopting the highly related Mus musculus Abl homologue as a template structure (PDB entry: 1OPJ , 0.175nm resolution). Active (open) Abl conformation is available as PDB entry 1OPL . Flexible docking of bosutinib to Abl was performed with Autodock v3.0 ( http://www.scripps.edu/mb/olson ). Results: Our binding hypothesis predicts that a) similarly to IM, the interaction between bosutinib and Abl seems to be more stable when the latter is in its inactive (closed) conformation; b) 21 Abl residues (including Y253, T315, F317 and F359 among others) surround bosutinib and engage H-bonds or Van der Waals interactions; c) bosutinib is likely to retain the ability to bind and inhibit the IM-resistant Y253H, M351T, F359V, F317L and E255V Abl mutants. In contrast, bosutinib binding to E255K and T315I mutants is predicted to be less efficient. Detailed models will be presented. Conclusions: Bosutinib is a promising second-line treatment for Ph+ leukemia patients harbouring several IM-resistant Abl mutations. The T315I remains the biggest hurdle for pharmacological therapy of Ph+ leukemias. Supported by European LeukemiaNet, AIRC, AIL, COFIN and FIRB projects, and by Fondazione del Monte di Bologna e Ravenna. No significant financial relationships to disclose.
Genomic Analyses Reveal Global Functional Alterations That Promote Tumor Growth and Novel Tumor Suppressor Genes in Natural Killer-Cell Malignancies
Authors: Can Kucuk, Javeed Iqbal, Ronald J. deLeeuw, Gopesh Srivastava, Wayne Tam, David Klinkebiel, Judith K. Christman, Lijun Shen, Karen Dybkaer, Wing Yan Au, Wan L. Lam, Wing C. Chan
Journal: Blood (2008)
The impact of the clinical pharmacist (CP) in reporting suspected adverse drug reactions (ADRs): the experience of the Medical Oncology Unit at the S.Orsola-Malpighi University Hospital
Authors: D. Grilli, F. Gelsomino, F. Massari, B. Angelelli, M. Tognetto, S. Restuccia, C. Puggioli, A. Ardizzoni
Journal: Annals of Oncology (2016)
OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues
Authors: Christina D. Drenberg, Alice A. Gibson, Stanley B. Pounds, Lei Shi, Dena P. Rhinehart, Lie Li, Shuiying Hu, Guoqing Du, Anne T. Nies, Matthias Schwab, Navjotsingh Pabla, William Blum, Tanja A. Gruber, Sharyn D. Baker, Alex Sparreboom
Journal: Cancer Research (2017)

Resistance to xenobiotic nucleosides used to treat acute myeloid leukemia (AML) and other cancers remains a major obstacle to clinical management. One process suggested to participate in resistance is reduced uptake into tumor cells via nucleoside transporters, although precise mechanisms are not understood. Through transcriptomic profiling, we determined that low expression of the ergothioneine transporter OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple cohorts of AML patients receiving treatment with the cytidine nucleoside analogue cytarabine. Cell biological studies confirmed OCTN1-mediated transport of cytarabine and various structurally related cytidine analogues, such as 2'deoxycytidine and gemcitabine, occurs through a saturable process that is highly sensitive to inhibition by the classic nucleoside transporter inhibitors dipyridamole and nitrobenzylmercaptopurine ribonucleoside. Our findings have immediate clinical implications given the potential of the identified transport system to help refine strategies that could improve patient survival across multiple cancer types where nucleoside analogues are used in cancer treatment. Cancer Res; 77(8); 2102-11. ©2017 AACR.
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Authors: Valerie Voon, T Celeste Napier, Michael J Frank, Veronique Sgambato-Faure, Anthony A Grace, Maria Rodriguez-Oroz, Jose Obeso, Erwan Bezard, Pierre-Olivier Fernagut
Journal: The Lancet Neurology (2017)
Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials
Authors: L. Dercle, S. Ammari, S. Champiat, C. Massard, C. Ferte, M. Texier, E. Lanoy, L. Taihi, R.-D. Seban, S. Aspeslagh, S. Antoun, L. Mahjoubi, N. Kamsu-Kom, C. Robert, A. Marabelle, M. Schlumberger, J.-C. Soria, S. Postel-Vinay
Journal: Annals of Oncology (2016)
Temozolimide and capecitabine in patients with refractory KRAS wildtype metastatic colorectal cancer. A phase II trial
Authors: C. Qvortrup, N. Keldsen, F. Andersen, H.A. Jensen, M. Krogh, L.W. Vestermark, J.K. Bjerregaard, P. Pfeiffer
Journal: Annals of Oncology (2016)
Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.
Authors: Juergen Finke, Claudia Schmoor, Wolfgang A. Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, Liisa Volin, Dominik Heim, Rainer Schwerdtfeger, Hartmut Bertz, Olga Grishina, Gerard Socie
Journal: Blood (2012)
RIZ1 negatively regulates IGF-1 expression in chronic myeloid leukemia
Authors: Sameer Ahmad Guru, Musadiq Ahmad Bhat, Ashikh Seethy, Mariyum Zuberi, Mamta P Sumi, Pooja Singh, P C Ray, N Gupta, Alpna Saxena
Journal: Annals of Oncology (2016)
Oral Anticancer Therapy Project: clinical utility of a specific home care nursing program
Authors: M. Cirillo, L. Carlucci, E. Baldini, C. Sacco, V. Zagonel, S. Leo, F.L. Rojas Llimpe, G. Tonini, M. Marialuisa, T. Alfredo, D. Farci, T. Sava, M. Zaninelli, V.M. Valori, A. Quaranta, F. Carrozza, B. Micheloni, F. Marchetti, G. Lunardi, S. Zamboni, C. Pinto, S. Gori
Journal: Annals of Oncology (2016)
Interaction Between Genotypes for HFE and TFR2 Genes Mutations and Iron Status in Brazilian Blood Donors
Authors: Rodolfo D Cancado, Paulo CJL Santos, Samuel Rostelato, Cristiane T Terada, Iris Gonzales, Rosário DC Hirata, Mario H Hirata, Carlos Chiattone, Elvira M Guerra-Shinohara
Journal: Blood (2008)
Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia
Authors: Brian A Walker, Christopher P Wardell, Kevin D Boyd, Emma M. Smith, Mette Nyegaard, Maria Teresa Petrucci, Pellegrino Musto, Hans E Johnsen, Antonino Neri, Faith E. Davies, Fiona M. Ross, Gareth J Morgan
Journal: Blood (2010)
Coculture of Pediatric Acute Lymphoblastic Leukemia (ALL) Blasts with CD40 Ligand Transfected Cells Leads to Changes of Surface Antigens and RNA Expression.
Authors: Daniel K. Stachel, Uta Eickelmann, Rita Meilbeck, Michael H. Albert, Raymund Buhmann, Michael Hallek, Irene Schmid
Journal: Blood (2005)
Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial
Authors: Ruth Mary de Tute, Andy C Rawstron, David A Cairns, Charlotte Pawlyn, Faith E Davies, Corinne Collett, Martin F Kaiser, John R Jones, Anna Waterhouse, Alina Striha, Gordon Cook, Matthew W Jenner, Nigel H Russell, Mark T Drayson, Walter M Gregory, Graham H Jackson, Gareth J Morgan, Roger G Owen
Journal: Blood (2016)
DDIS-02. AN ENGINEERED IN VITRO SYNTHESIZED PROTEIN ZR30 EXPRESSES ITS ANTI-CANCER EFFECT IN THE EXTRACELLULAR COMPARTMENT OF DIFFERENT GLIOMA CELL SUBPOPULATIONS IN INTRACRANIAL XENOGRAFT MODELS
Authors: Yanyan Li, Chuaniin Liu, Qingyue Wang, Xiaoxiao Han, Yong Han, Xiong-Hui Chen, Eric Siegel, Kambiz Afrasiabi, Mark Linskey, You-Xin Zhou, Yi-Hong Zhou
Journal: Neuro-Oncology (2016)

Therapeutants for successful cancer treatment should be designed to inhibit the growth and invasive features of the cancer cell as well as the cues of the tumor microenvironment. We have reported that glioma cells transduced with a construct to express an EFEMP1-derived tumor suppressor protein (ETSP) possesses these therapeutic effects with multiple tumor growth suppression mechanisms of action (MOA), including targeting EGFR/AKT-mediated cell growth, MMP2-mediated cell invasion and angiogenesis, and NOTCH-mediated cancer cell stemness. It appears that these anti-cancer effects originate in the extracellular compartment. Hence an in vitro synthesized protein, ZR30, based on the sequence of ETSP, with removal of the signal peptide was studied for its effect on these oncogenic proteins and its therapeutic potential. The results showed a positive effect of ZR30 in suppressing extracellular activation of MMP2 in multiple glioma cell lines. Two glioma cell subpopulations with high proliferative and angiogenic features, namely tumor mass-forming cells (TMC) and highly invasive stem-like tumor initiating cells (STIC) that were differentially enriched in the U251 and U251NS cell lines, respectively, were effectively targeted by 2 or 3-day exposure to ZR30 in culture, as evidenced by their decreased expression of EGFR, NOTCH, and their reduced AKT activities. Consistently, the growth of both glioma cell lines in an orthotopic environment was equally suppressed by ZR30 given at the stage of late tumor formation. The therapeutic potential of ZR30 was validated by markedly increased survival of mice harboring U251 xenografts, following only one intra-tumoral dose, at the time of early tumor formation.
Severe Adverse Events of Allogeneic Related Peripheral Blood Stem Cell Donors -Results of Nation-Wide 3,262 Consecutively and Prospectively Registered Case-Survey in Japan and of Its Comparison to the Outcome of Retrospective Survey Shared with EBMT for Stem Cell Donors.
Authors: Yoshihisa Kodera, Shunichi Kato, Mine Harada, Shintaro Shiobara, Nobuyuki Hamajima, Yasuo Morishima, Mitsune Tanimoto, Shigetaka Asano, Yasuo Ikeda, Hiroo Dohi, Tatsutoshi Nakahata, Masahiro Imamura, Keisei Kawa, Yoichi Takaue, Yoshinobu Kanda, Kazuhito Yamamoto, Genevieve Favre, Alois Gratwohl
Journal: Blood (2005)
The association of clinical-pathologic factors and Oncotype Dx recurrence score (RS) in the outcome of early stage breast cancer.
Authors: Manjeet Chadha, Robert Stewart, Jonathan Wallach
Journal: Journal of Clinical Oncology (2015)

55 Background: Oncotype Dx recurrence score (RS) is routinely used to guide systemic therapy based on the estimated risk for distant relapse. Patients with early stage disease are also at risk for locoregional recurrence, and in some instances local relapse is the only site of failure. The objective of this study is to evaluate patient outcomes in association with known clinical-pathologic risk factors and RS. Observations in context of known clinical-pathologic features and RS may have important clinical implications relative to adjuvant locoregional therapy. Methods: This is an IRB approved retrospective study that includes patients with unilateral breast cancer and in whom the RS was reported. A total of 716 patients met this defined criteria. Seventy two percent underwent breast conserving therapy (BCS) and 28% underwent mastectomy; 68% had stage I and the remaining had &gt; Stage II disease.The clinical-pathologic variables including age, stage, BRCA mutation, extent of surgery, and RS were studied in evaluating patient outcomes. Results: The median age was 56 years (27 to 84 years). The overall distribution of RS reported as low (18), intermediate (19-30), and high ( &gt; 31) was 59%, 31%, and 10%, respectively. This distribution ratio was no different among patients treated with BCS and mastectomy. However, among BRCA mutation carriers there was a higher incidence of the high RS.Overall, the median follow up was over 3 years, and 25% of the patients have been followed over 5 years. The 3-year and 5-year any relapse-free survival was 93% and 89%, respectively. Age was significantly associated with observed inferior any relapse-free survival; 85% and 91% in women &lt; 40 years vs &gt; 40 years, respectively (p = 0.018). On univariate analysis, RS had no significant association with local regional relapse free survival. Further, associations between the clinical-pathologic features and RS using multivariate analysis will be presented. Conclusions: Observations with early follow up do not suggest a select role of RS in guiding risk tailored local regional therapy. Longer follow will further our understanding of patients at risk for local regional relapse.
Gender and chemotherapy-related toxicity in colon cancer: an analysis of the PETACC-3 trial conducted by the EORTC GI-group
Authors: V. Cristina, J. Mahachie, M. Mauer, C. Csajka, D. Cunningham, E. Van Cutsem, A. Roth, A.D. Wagner
Journal: Annals of Oncology (2016)
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab
Authors: J. Bagel, S. Tyring, K.C. Rice, D.H. Collier, G. Kricorian, J. Chung, J. Iles, B.S. Stolshek, A. Kaliyaperumal, K.A. Papp
Journal: British Journal of Dermatology (2017)

Some patients with plaque psoriasis experience secondary failure of tumour necrosis factor inhibitor therapy.To evaluate efficacy, safety and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure.This phase IV open-label single-arm estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static Physician's Global Assessment (sPGA) score 0/1 (clear/almost clear). Patients subsequently lost response, defined as sPGA ≥ 3 or loss of 50% improvement in Psoriasis Area and Severity Index (PASI 50). At baseline, patients had involved body surface area ≥ 10%, sPGA ≥ 3 and PASI ≥ 10. Antiadalimumab antibodies (ADAs) were measured at screening. Patients received etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly. The primary end point was sPGA 0/1 at week 12 (intention-to-treat analysis; no hypothesis tested). Additional outcomes included rates of sPGA 0/1, PASI responses, safety, PROs of itch, pain and flaking, Dermatology Life Quality Index, treatment satisfaction and Work Productivity and Activity Impairment questionnaire.Sixty-four patients enrolled; 67% had ADAs. sPGA 0/1 rates at week 12 were 39·7% [95% confidence interval (CI) 27·6-52·8; primary end point] and 45% (95% CI 29·3-61·5) for patients positive for ADAs and 35% (95% CI 15·4-59·2) for patients negative for ADAs. PASI 75 response rates at week 12 were 47·5% (95% CI 31·5-63·9) for patients who were positive for ADAs and 50% (95% CI 27·2-72·8) for patients negative for ADAs. No new safety signals were observed. PROs of itch, pain and flaking consistently improved at week 12 and were maintained through week 24.Patients with psoriasis who experienced secondary failure of adalimumab achieved satisfactory response to etanercept regardless of ADA status.
Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC)
Authors: J. Lahmar, L. Mezquita, S. Koscielny, F. Facchinetti, M.V. Bluthgen, J. Adam, A. Gazzah, J. Remon, D. Planchard, J.-C. Soria, C. Caramella, B. Besse
Journal: Annals of Oncology (2016)
Regorafenib (R) versus placebo (P) in soft tissue sarcomas (STS): analysis of genetic prognostic and predictive factors
Authors: T. Brodowicz, B. Liegl-Atzwanger, E. Tresch-Bruneel, E. Bogart, O. Mir, J.-Y. Blay, K. Kashofer, A. Le Cesne, R. Hamacher, N. Penel
Journal: Annals of Oncology (2016)